AMENDMENTS TO THE CLAIMS

1. – 17. (Cancelled)

18. (Currently Amended) A method of treating a patient having or at risk of a thrombotic disease or atherosclerosis, comprising: administering to said patient an effective dose of a humanized immunoglobulin, wherein said humanized immunoglobulin comprises

(a) complementarity determining regions having amino acid sequences RFWMS (residues 49-53 of ~~SEQ ID NO: 5~~ SEQ ID NO: 6), EVNPDNNTMNYTPSLKD (residues 68-84 of ~~SEQ ID NO: 5~~ SEQ ID NO: 6) and PPYYGSYGGFAY (residues 117-128 of ~~SEQ ID NO: 5~~ SEQ ID NO: 6), in the heavy chain, and RASENIYNNLA (residues 44-54 of ~~SEQ ID NO: 7~~ SEQ ID NO: 8), AATNLAD (residues 70-76 of ~~SEQ ID NO: 7~~ SEQ ID NO: 8) and GHLWTSPYT (residues 109-117 of ~~SEQ ID NO: 7~~ SEQ ID NO: 8), in the light chain, and

(b) framework regions of human antibody, wherein the framework region in the heavy chain is at least 85% homologous to ~~SEQ ID NO: 5~~ SEQ ID NO: 6 and the framework region in the light chain is at least 85% homologous to ~~SEQ ID NO: 7~~ SEQ ID NO: 8.

19. – 20. (Cancelled)

21. (Previously Presented) The method of claim 18, wherein the treatment is for stroke, transient ischemic attack, unstable angina, acute myocardial infarction, peripheral vascular disease, deep vein thrombosis, hemolytic uremic syndrome, hemolytic anemia, acute renal failure, thrombotic thrombocytopenic purpura, ischemic complications caused by acute and subacute thrombosis, restenosis after endovascular intervention or preventing ischemic complications caused by reocclusion after thrombolytic treatment in acute myocardial infarction as an adjunctive therapy.

22. (Cancelled)

23. (Previously Presented) The method of claim 18, wherein the immunoglobulin is a Fab, a $F(ab')_2$, or a Fv.

24. (Previously Presented) The method of claim 18, wherein the immunoglobulin is a single chain antibody produced by joining VL and VH with a DNA linker.

25. (Previously Presented) The method of claim 18, wherein the immunoglobulin has an IgG_2 or IgG_4 immunoglobulin subtype.

26. (Previously Presented) The method of claim 18, wherein the framework region is a Cγ2 or Cγ4 region.

27. (Previously Presented) The method of claim 18, wherein the immunoglobulin is admixed with a pharmaceutically acceptable carrier.